Anemia in neoplastic disease
ICD-10 D63.0 is a billable code used to indicate a diagnosis of anemia in neoplastic disease.
Anemia in neoplastic disease refers to a type of anemia that occurs as a consequence of malignancies. This condition can arise from various mechanisms, including bone marrow infiltration by neoplastic cells, chronic disease processes, or treatment-related effects such as chemotherapy or radiation. Aplastic anemia, a severe form of bone marrow failure, can also be associated with neoplastic diseases, leading to a significant reduction in red blood cell production. The acquired anemias linked to neoplastic diseases often present with symptoms such as fatigue, pallor, and weakness, which can significantly impact the patient's quality of life. The diagnosis of anemia in this context requires careful evaluation of the patient's medical history, laboratory tests including complete blood counts, and possibly bone marrow biopsies to determine the underlying cause. Management may involve treating the underlying malignancy, blood transfusions, or the use of erythropoiesis-stimulating agents. Accurate coding is essential for appropriate treatment and reimbursement.
Detailed documentation of the patient's cancer diagnosis, treatment history, and laboratory results related to anemia.
Patients undergoing chemotherapy who develop anemia, or those with bone marrow involvement from malignancies.
Ensure that the relationship between the neoplastic disease and anemia is clearly documented to support coding.
Comprehensive patient history, including chronic diseases and medications that may contribute to anemia.
Management of patients with chronic illnesses and anemia, particularly in the context of cancer.
Documenting the severity of anemia and its impact on the patient's overall health is crucial.
Used when obtaining blood samples for anemia evaluation.
Document the reason for blood draw and any relevant clinical findings.
Ensure that the blood draw is linked to the anemia diagnosis.
Anemia in neoplastic disease is primarily caused by bone marrow infiltration by cancer cells, leading to decreased red blood cell production, as well as treatment-related effects such as chemotherapy.
